The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on implementing changes to the advertising and promotion of medicines authorised in the UK after 1 January 2025, following the agreement on human medicines as part of the Windsor Framework. The guidance confirms that, from 1 January 2025, all medicines in the UK will be licensed by the MHRA and authorised under the Human Medicines Regulations 2012 (HMRs), SI 2012/1916 (as amended). Marketing authorisation holders (MAHs) will still be able to have a Northern Ireland (NI) marketing authorisation (MA), and, in exceptional circumstances, the MHRA will retain the right to issue Great Britain MAs after 1 January 2025 to safeguard the interests of patients’ health within the UK. Additionally, advertisements to Persons Qualified to Prescribe or Supply will be required to list a series of particulars for the medicinal product being advertised, such as the product licence number and the name and address of the MAH. The guidance also states that, from 1 January 2025, the EU licence number assigned to licences in respect of NI will no longer apply and suggests that the number should be phased out 'at the earliest available opportunity.'